Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 3.16% 8.15 8.00 8.30 8.45 7.90 7.90 3,224,082 11:55:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 22

Evgen Pharma Share Discussion Threads

Showing 8201 to 8219 of 8225 messages
Chat Pages: 329  328  327  326  325  324  323  322  321  320  319  318  Older
DateSubjectAuthorDiscuss
21/4/2021
20:42
All in the mix regardless Bumpa, although tomorrow's action might give us a clue and I still reckon given the larger trades reported late almost every day since the placing, there's been an orderly accumulation of cheap shares in progress. Gl :-)
moneymunch
21/4/2021
20:07
Hard to say on that 845k, though I’d think a sell more likely - got printed before the close though, curiously. To be fair analyzing the big trades has got us absolutely nowhere up to now...
bumpa33
21/4/2021
19:06
Easiest job going if Prof Chalmers confirms efficacy for Covid/ARDS, and yes indeed PDT, and not just Roche who might be interested and every chance that Boris and co will want to keep it British...;-))))
moneymunch
21/4/2021
18:59
Dr Helen Kuhlman CBO This is where Dr Kuhlman could well prove a good appointment with her experience in government funding and equity investment
kingalf
21/4/2021
18:59
I see that Roche announced today that they had ceased investigating two potential drugs to treat COVID patients with pneumonia. Therefore, Evgen's potential solution is more important than ever if it is successful. Perhaps they would be keen to partner with Evgen? hTTps://www.fiercebiotech.com/biotech/roche-culls-two-covid-drug-hopefuls-amid-q1-clear-out
pdt
21/4/2021
18:31
It's timed at 16.13pm and priced at 8.3p which suggests a buy....the accumulation of cheap shares continues imho Gl ;-)
moneymunch
21/4/2021
17:49
Can we really be 100% certain that it was a buy, after all the market makers sold a fair bit on to buyers at 8.4/8.5, maybe the seller left them with this order earlier in the day, and it was only trade reportd when the market makers felt that further volume buying was unlikely today. But if it was a sell it does mean that the share register is tightning up.
mesquida
21/4/2021
17:38
Exciting times...:-)
moneymunch
21/4/2021
17:18
845k buy..all bodes well. Gla :-)
moneymunch
21/4/2021
12:59
htTps://www.gov.uk/government/news/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn
moneymunch
21/4/2021
09:20
Evgen Pharma: Johns Hopkins research further assesses the potential of company's drug to treat COVID-19 Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus Work carried out by researchers at the world-famous Johns Hopkins in the US appears to underline the potential of Evgen Pharma PLC’s (LON:EVG) lead drug in battling Coronavirus (COVID-19). Researchers found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed Coronavirus. In addition, the Johns Hopkins team went on to demonstrate the drug inhibited toxicity to cells as a pre-treatment before inoculation while also acting “synergistically” with antiviral drug remdesivir. Results from the lab-based work formed the basis of a recent pre-print publication that was released before it was peer-reviewed “given the urgency of the current pandemic”. SFX-01 is being administered to treat people with severe COVID in the STAR clinical trial being carried out by scientists at Dundee University. An interim analysis of the first hundred patients in the STAR study is expected sometime this quarter. Of the Johns Hopkins update, Evgen chief executive, Huw Jones, said: “If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study.”
moneymunch
21/4/2021
09:14
Those last three trades are buys
awise355
21/4/2021
09:11
The Government’s chief scientific adviser Sir Patrick Vallance said: “The speed at which vaccines and therapeutics such as dexamethasone have been identified and deployed against Covid-19 has been critical to the pandemic response. “Antivirals in tablet form are another key tool for the response. “They could help protect those not protected by or ineligible for vaccines. “They could also be another layer of defence in the face of new variants of concern.” Dr Nikita Kanani, medical director of primary care for NHS England said: “The NHS has put research into reality at record speed during the pandemic and this taskforce will now help us to identify and roll out even more new, convenient treatments for patients with Covid-19.” Commenting on the announcement, Dr Penny Ward, visiting professor in pharmaceutical medicine at Kings College London, said: “Antiviral treatment of influenza has been shown to reduce hospitalisation and prevent death in epidemic and pandemic waves and a similar, preferably simple to use antiviral, suitable for use in the community can add to the range of interventions critical to enable us to remain on top of the Covid pandemic even in the event of the emergence of viral variants insensitive to vaccines.” She said that there are a number of early phase trials looking at oral antiviral medications.
moneymunch
21/4/2021
08:36
I'm in too. Been on my watch list for ages. Looks like its about to get interesting. GLA.
ricric
21/4/2021
08:20
A little top up for me this morning. The story just gets more interesting.
brasso3
21/4/2021
08:16
Watching the covid/ARDS story here has been like watching someone piece together a giant jigsaw puzzle. We’re now just a few - albeit crucial - pieces away from completing the picture.
bumpa33
21/4/2021
08:16
What else can it be that could be ready by Autumn, apart from SFX-01, where efficacy results are expected imminently on the back of and John Hopkins University stunning research on Sulforaphane???? Gla Holders ;-) A PILL to kill third wave: Boris Johnson launches 'ambitious' new 'antivirals taskforce' so Britons can take tablets for Covid at home 'by autumn' Government is launching an 'antivirals taskforce' to find two drugs by autumn for people to take at home They will be pills to take at home before serious Covid develops, officials say, reducing need for hospital beds Government staff, university scientists and pharmaceutical company experts will be on panel Most will be vaccinated by that time but drugs will help control local outbreaks and squash spikes in cases htTps://www.dailymail.co.uk/news/article-9491869/Coronavirus-Britain-pills-treat-Covid-autumn.html
moneymunch
21/4/2021
07:33
Well, they now admit we will need anti-virals. Time for EVG to deliver. If we can, no doubting now the impact this will have...
bumpa33
21/4/2021
07:29
You are spot on Moneymunch; "Currently, there are no orally available medications for prophylaxis for those exposed to SARS-CoV-2 and limited therapeutic options for those who develop COVID-19. We evaluated the antiviral activity of sulforaphane (SFN), a naturally occurring, orally available, well-tolerated, nutritional supplement present in high concentrations in cruciferous vegetables with limited side effects. SFN inhibited in vitro replication of four strains of SARS-CoV-2 as well as that of the seasonal coronavirus HCoV-OC43. Further, SFN and remdesivir interacted synergistically to inhibit coronavirus infection in vitro" The Antivirals Taskforce want one in tablet form and one that works in combination with another antiviral. They are describing Sulforadex!
pdt
Chat Pages: 329  328  327  326  325  324  323  322  321  320  319  318  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210422 01:15:20